Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with ...

The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...

A comprehensive guide to the practice-changing, paradigm-shifting studies across benign urologic conditions. At the 2026 Annual Meeting of the American Urological Association in Washington, DC, the P2 ...

A comprehensive guide to the practice-changing, paradigm-shifting studies across urologic oncology. Urologists will soon gather in Washington, DC, for the 2026 Annual Meeting of the American ...

Pre-operative counseling should frame vasectomy as intended permanent contraception, individualized to reproductive goals, and can be delivered virtually or in person while directly addressing ...

Boxed warnings were removed from Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva, spanning progestogen-only, systemic estrogen-only, topical vaginal estrogen, and combined systemic ...

VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...

Enolen's fast track designation by the FDA highlights its potential to address unmet needs in early-stage prostate cancer treatment. The implant technology aims to deliver high local drug ...

In this peer exchange, expert faculty opened the discussion by outlining the evolving management of metastatic castration-sensitive prostate cancer (mCSPC). Panelists noted that androgen deprivation ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

The combination of enfortumab vedotin and pembrolizumab improved event-free survival, overall survival, and pathological complete response in muscle-invasive bladder cancer patients ineligible for ...

The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...